Man Group’s NextCure NXTC Stock Holding History

Man Group’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,308	Closed	-$157K	–	2054
2021 Q1	$157K	Sell	1,308 -8,084	-86%	-$1.17M	﹤0.01%	1771
2020 Q4	$1.23M	Sell	9,392 -756	-7%	-$97.7K	0.01%	1359
2020 Q3	$1.07M	Buy	+10,148	New	+$1.25M	﹤0.01%	1354

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Man Group's NXTC Position: Q2 2021 in Review

Man Group sold out of NextCure (NXTC) in Q2 2021, closing a stake of 1,308 shares — an estimated $157K sold.

Man Group first reported a position in NXTC in Q3 2020 and held it in 3 quarters. The position peaked at $1.23M in Q4 2020. 78 funds tracked by Wall St. Rank hold NXTC as of Q2 2021.

Man Group reported no remaining NextCure position as of Q2 2021 after selling out during the quarter.
Man Group sold 1,308 NextCure shares in Q2 2021, an estimated $157K.
Man Group first reported a position in NextCure in Q3 2020 and held it in 3 quarters.
Man Group's NextCure position peaked at $1.23M in Q4 2020.
78 funds tracked by Wall St. Rank held NextCure as of Q2 2021.

Based on Man Group's 13F filing for Q2 2021, filed 16 Aug 2021.